Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.0550 (2.74%) ($5.0550 - $5.0550) on Tue. Mar. 30, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.58% (three month average) | RSI | 47 | Latest Price | $5.0550(2.74%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.2% a day on average for past five trading days. | Weekly Trend | ADAP declines -3.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) ACES(53%) PEJ(31%) REMX(17%) UNG(41%) SIL(23%) | Factors Impacting ADAP price | ADAP will decline at least -2.29% in a week (0% probabilities). XRT(21%) IFRA(-47%) INDA(1%) IDRV(24%) IPO(37%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.29% (StdDev 4.58%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.68(-153.02%) | Inflection Point | Yes | Resistance Level | $5.25 | 5 Day Moving Average | $5.08(-0.49%) | 10 Day Moving Average | $5.22(-3.16%) | 20 Day Moving Average | $5.25(-3.71%) | To recent high | -26.1% | To recent low | 0.6% | Market Cap | $782m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |